Cogent Biosciences Files 8-K: Material Agreement & Financials
Ticker: COGT · Form: 8-K · Filed: Jul 10, 2025 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-results
TL;DR
Cogent Biosciences inked a new deal and dropped financials, check the 8-K.
AI Summary
On July 7, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement. The company also reported its results of operations and financial condition, with financial statements and exhibits included. Cogent Biosciences, Inc. is incorporated in Delaware and its principal executive offices are located in Waltham, Massachusetts.
Why It Matters
This filing indicates a significant new agreement for Cogent Biosciences, which could impact its future operations and financial performance. Investors should review the details of the agreement and financial results.
Risk Assessment
Risk Level: medium — Material definitive agreements and financial condition updates can significantly impact a company's stock price and future prospects.
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Registrant
- July 7, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of incorporation
- 001-38443 (identifier) — Commission File Number
- 46-5308248 (identifier) — I.R.S. Employer Identification No.
- 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451 (address) — Address of principal executive offices
- Unum Therapeutics Inc. (company) — Former company name
- 20180402 (date) — Date of name change from Unum Therapeutics Inc.
FAQ
What is the nature of the material definitive agreement entered into by Cogent Biosciences, Inc. on July 7, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text. Further review of the full filing is required.
What specific results of operations and financial condition are reported by Cogent Biosciences, Inc.?
The filing states that results of operations and financial condition are reported, along with financial statements and exhibits. The specific financial details are not included in the provided text.
When was Cogent Biosciences, Inc. incorporated and in which jurisdiction?
Cogent Biosciences, Inc. was incorporated in Delaware.
What is the address of Cogent Biosciences, Inc.'s principal executive offices?
The principal executive offices of Cogent Biosciences, Inc. are located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451.
Has Cogent Biosciences, Inc. previously operated under a different name?
Yes, Cogent Biosciences, Inc. was formerly known as Unum Therapeutics Inc., with a name change occurring on April 2, 2018.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 10, 2025 regarding Cogent Biosciences, Inc. (COGT).